UA111462C2 - Use of (s)-2,6-diaminohexanoic acid 3-methyl-1,2,4-triazolyl-5-thioacetate as active ingredient of pharmaceutical formulations intended for prevention and treatment of impaired vital functions of central nervous system in severe forms of ethanol intoxication - Google Patents
Use of (s)-2,6-diaminohexanoic acid 3-methyl-1,2,4-triazolyl-5-thioacetate as active ingredient of pharmaceutical formulations intended for prevention and treatment of impaired vital functions of central nervous system in severe forms of ethanol intoxicationInfo
- Publication number
- UA111462C2 UA111462C2 UAA201600367A UAA201600367A UA111462C2 UA 111462 C2 UA111462 C2 UA 111462C2 UA A201600367 A UAA201600367 A UA A201600367A UA A201600367 A UAA201600367 A UA A201600367A UA 111462 C2 UA111462 C2 UA 111462C2
- Authority
- UA
- Ukraine
- Prior art keywords
- thioacetate
- triazolyl
- prevention
- methyl
- treatment
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Винахід належить до галузі медицини та фармацевтики і стосується застосування (S)-2,6-діаміногексанової кислоти 3-метил-1,2,4-триазоліл-5-тіоацетату як активної основи лікарських засобів для профілактики та лікування порушень життєзабезпечуючих функцій центральної нервової системи при важких формах гострого отруєння етанолом.FIELD: medicine, pharmaceutics. SUBSTANCE: invention relates to the use of (S) -2,6-diaminohexanoic acid 3-methyl-1,2,4-triazolyl-5-thioacetate as an active drug base for the prevention and treatment of disorders of the central nervous system's vital functions. in severe forms of acute ethanol poisoning.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAA201600367A UA111462C2 (en) | 2016-01-16 | 2016-01-16 | Use of (s)-2,6-diaminohexanoic acid 3-methyl-1,2,4-triazolyl-5-thioacetate as active ingredient of pharmaceutical formulations intended for prevention and treatment of impaired vital functions of central nervous system in severe forms of ethanol intoxication |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAA201600367A UA111462C2 (en) | 2016-01-16 | 2016-01-16 | Use of (s)-2,6-diaminohexanoic acid 3-methyl-1,2,4-triazolyl-5-thioacetate as active ingredient of pharmaceutical formulations intended for prevention and treatment of impaired vital functions of central nervous system in severe forms of ethanol intoxication |
Publications (1)
Publication Number | Publication Date |
---|---|
UA111462C2 true UA111462C2 (en) | 2016-04-25 |
Family
ID=55861420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201600367A UA111462C2 (en) | 2016-01-16 | 2016-01-16 | Use of (s)-2,6-diaminohexanoic acid 3-methyl-1,2,4-triazolyl-5-thioacetate as active ingredient of pharmaceutical formulations intended for prevention and treatment of impaired vital functions of central nervous system in severe forms of ethanol intoxication |
Country Status (1)
Country | Link |
---|---|
UA (1) | UA111462C2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2679447C1 (en) * | 2018-02-13 | 2019-02-11 | Общество С Ограниченной Ответственностью "Научно-Производственное Объединение "Фарматрон" | Application of l-lysine tiazototate as an active basis for medicines of hepatoprotective and detoxicative action |
-
2016
- 2016-01-16 UA UAA201600367A patent/UA111462C2/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2679447C1 (en) * | 2018-02-13 | 2019-02-11 | Общество С Ограниченной Ответственностью "Научно-Производственное Объединение "Фарматрон" | Application of l-lysine tiazototate as an active basis for medicines of hepatoprotective and detoxicative action |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201800064A1 (en) | 1,1,1-TRIFTOR-3-HYDROXYPROPAN-2-IL CARBAMATE DERIVATIVES AND 1,1,1-TRIFTOR-4-HYDROXYBUTAN-2-IL CARBAMATE DERIVATIVES AS MIGL INHIBITORS | |
BR112018073663A2 (en) | Spiro-lactam nmda receptor modulators and their uses | |
EA202090573A1 (en) | COMPOSITIONS OF NIRAPARIBA | |
BR112019001768A2 (en) | spiro-lactam receptor modulators and their uses | |
BR112015010663A8 (en) | sustained release oral dosage forms, and use of ruxolitinib or a pharmaceutically acceptable salt thereof | |
EA201100032A1 (en) | PYRIDINE COMPOUNDS | |
EA201992162A1 (en) | COMPOSITIONS BASED ON NIRAPARIB | |
BR112015018087A8 (en) | compound, pharmaceutical composition and use | |
EA201991374A1 (en) | WATER-SOLUBLE DERIVATIVE OF EPIALLOPRANANOLONE AND ITS APPLICATION | |
BR112015030315A2 (en) | 4-alkynylimidazole derivative and medicament comprising the same as active ingredient | |
EA202091020A1 (en) | SUBSTITUTED IMIDAZOPYRIDINAMIDES AND THEIR APPLICATION | |
MY191980A (en) | Formulations containing an extract of echinacea and linoleic acid derivatives | |
EA201590797A1 (en) | PREPARATIONS WITH THE MODIFIED PROBE RELEASE | |
TR201821157T4 (en) | ORAL APPLICATION SOLID COMPOSITION CONTAINING IBANDRONIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT AND VITAMIN D. | |
MX2017013636A (en) | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles. | |
EA202191684A1 (en) | DRUG CONTAINING URSODEOXYCHOLIC ACID FOR TREATMENT OR PREVENTION OF PRESBIOPIA | |
MX2021008536A (en) | Modified release tablet formulations containing phosphodiesterase inhibitors. | |
BR112018073419A2 (en) | combination, use of combination, method for treatment, compound, method for treatment of alzheimer's disease and pharmaceutical composition | |
WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib | |
UA111462C2 (en) | Use of (s)-2,6-diaminohexanoic acid 3-methyl-1,2,4-triazolyl-5-thioacetate as active ingredient of pharmaceutical formulations intended for prevention and treatment of impaired vital functions of central nervous system in severe forms of ethanol intoxication | |
WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
EA201991817A1 (en) | Intranasal Composition Including Betagistin | |
EA202190317A1 (en) | DRUG FOR EXTERNAL USE | |
EA201990550A1 (en) | OPHTHALMIC DRUG INCLUDING THE ASOLIC COMPOUND | |
WO2017205779A3 (en) | Compositions and methods for treating disorders related to inflammasome activity and il-1alpha expression |